NCT03127605Approved For Marketing不适用
Inotuzumab Ozogamicin - PF-05208773
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
- Pfizer
研究概览
简要总结
Inotuzumab Ozogamicin Expanded Access Program
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphomaB-cell Lymphoma RefractoryNCT01535989Cristiana Sessa25
已完成
2 期
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic LeukemiaAcute Lymphocytic LeukemiaNCT01363297Pfizer72
进行中（未招募）
1 期
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALLB-cell Acute Lymphoblastic LeukemiaNCT03962465University of Virginia36
进行中（未招募）
1 期
A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Patients with Indolent (slow-growing) Non-Hodgkin Lymphoma (a type of blood cancer) Who Have Failed Treament with Rituximab and Chemotherapy (a drug that prevents the growth of tumor cells) or Radioimmunotherapy(a drug that kills tumor cells with radiation)Indolent Non-Hodgkin's LymphomaMedDRA version: 14.1Level: PTClassification code 10065856Term: Non-Hodgkin's lymphoma unspecified histology indolentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-001635-34-BEWyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA81
进行中（未招募）
不适用
A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With IndolentNon-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or RadioimmunotherapyIndolent Non-Hodgkin's LymphomaMedDRA version: 9.1Level: LLTClassification code 10065856Term: Non-Hodgkin's lymphoma unspecified histology indolentEUCTR2008-001635-34-HUWyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research & Development60